Antihypertensive drugs and the risk of incident rosacea

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 130-136

  Spoendlin, J ^a   Voegel, J J ^b   Jick, S S ^c   Meier, C R ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Galderma R and D   (France)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; SPIRONOLACTONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; ROSACEA; UNITED KINGDOM; ADOLESCENT; CHEMICALLY INDUCED; CHILD; DRUG ERUPTIONS; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; FEMALE; HUMANS; HYPERTENSION; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK FACTORS; ROSACEA; YOUNG ADULT;

EID: 84904991289     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12838     Document Type: Article

References (31)

1. Wilkin J, Dahl M, Detmar M, et al,. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
2. Schwab VD, Sulk M, Seeliger S, et al,. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 53-62.
3. Steinhoff M, Buddenkotte J, Aubert J, et al,. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.
4. Aubdool AA, Brain SD,. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc 2011; 15: 33-9.
5. Yamasaki K, Gallo RL,. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.
6. Powell FC,. Clinical practice. Rosacea. N Engl J Med 2005; 352: 793-803.
7. Culp B, Scheinfeld N,. Rosacea: a review. P T 2009; 34: 38-45.
8. Elewski BE, Draelos Z, Dreno B, et al,. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.
9. Odom R, Dahl M, Dover J, et al,. Standard management options for rosacea, part 2: options according to subtype. Cutis 2009; 84: 97-104.
10. Craige H, Cohen JB,. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53: 881-4.
11. Hsu CC, Lee JY,. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol 2012; 67: 491-3.
12. Hsu CC, Lee JY,. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol 2011; 147: 1258-60.
13. Wilkin JK,. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20: 202-5.
14. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Available at: http://cks.nice.org.uk/ rosacea&x0021;scenariorecommendation (last accessed 24 February 2014).
15. Natale F, Cirillo C, Granato C, et al,. Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation. Hypertens Res 2011; 34: 790-1.
16. National Institute for Health and Care Excellence. Hypertension-Clinical Management of Primary Hypertension in Adults. London: National Institute for Health and Care Excellence, 2011.
17. National Institute for Health and Care Excellence. MI: Secondary Prevention. London: National Institute for Health and Care Excellence, 2007.
18. National Institute for Health and Care Excellence. Chronic Heart Failure-National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: National Institute for Health and Care Excellence, 2010.
19. National Institute for Health and Care Excellence. Stroke-National Clinical Guideline for Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack. London: National Institute for Health and Care Excellence, 2008.
20. Khan NF, Harrison SE, Rose PW,. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128-36.
21. Walley T, Mantgani A,. The UK general practice research database. Lancet 1997; 350: 1097-9.
22. Wood L, Martinez C,. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27: 871-81.
23. Spoendlin J, Voegel JJ, Jick SS, et al,. A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012; 167: 598-605.
24. WHO Collaborating Centre for Drug Statistics and Methodology. Available at: http://www.whocc.no/atc-ddd-index/?code=C08 (last accessed 24 February 2014).
25. Grossman E, Messerli FH,. Calcium antagonists. Prog Cardiovas Dis 2004; 47: 34-57.
26. Powell FC,. What's going on in rosacea? J Eur Acad Dermatol Venereol 2000; 14: 351-2.
27. Frishman WH, Saunders E,. Beta-adrenergic blockers. J Clin Hyperten 2011; 13: 649-53.
28. British National Formulary. Available at: http://www.medicinescomplete. com/mc/bnf/current/PHP944-propranolol-hydrochloride.htm?q=propranolol&t= search&ss=text&p=1-hit (last accessed 24 February 2014).
29. Layton A, Thiboutot D,. Emerging therapies in rosacea. J Am Acad Dermatol 2013; 69 (6 Suppl. 1): S57-65.
30. Abram K, Silm H, Maaroos HI, et al,. Subjective disease perception and symptoms of depression in relation to healthcare-seeking behaviour in patients with rosacea. Acta Derm Venereol 2009; 89: 488-91.
31. Holme SA, Scott-Lang VE, Ooi ET, et al,. The South-East Scotland Dermatology Workload Study: 30 years. analysis. Br J Dermatol 2012; 167: 123-30.